Got back pain questions? Our Back Wellness Coaches have answers. Text Us Now at 412.419.2225. It's FREE!

Login Signup

Why Insurers Won't Cover This Life-Saving Drug

Published July 30, 2019
Category: Medication

This $2.1 million single dose drug treats children with spinal muscular atrophy. Unfortunately, the staggering cost is proving to be too substantial for most people who have SMA. In regards to the drug's price tag, Zolgensma was designed to provide long-term benefit after a one-time infusion. Insurance plans  refused to pay for the costly drug because it's a type of gene therapy, a service they don't historically cover. 

Full Article
Last change: July 30, 2019


Be the first to comment. Login or sign up.